Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo Wellcome Licenses Rosetta s Resolver Software

NEW YORK, Dec 11 - Rosetta Inpharmatics said Monday that it had licensed its Resolver Expression Data Analysis System to Glaxo Wellcome.

Glaxo Wellcome will use the system, which is exclusively distributed by Agilent Technologies, to to analyze gene expression data.

The Resolver software can be used with a variety of DNA chip technologies, including Agilent’s microarrays and Affymetrix GeneChip microarrays.

" It significantly complements our in-house development programs and will help maintain the company's position at the leading edge of applying genomics technologies in the pursuit of new treatments,” said Eric Meldrum, group leader for molecular and cellular biology at Glaxo Wellcome.

Glaxo Wellcome was not immediately available to comment on its decision to license the Resolver software.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.